Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. Bioorg Med Chem Lett. 2016 Oct 15;26(20):4865-4869. PMID:27666635 DOI:10.1016/j.bmcl.2016.09.041
Target: ABL1 Tyrosine-protein kinase ABL1 P00519 Homo sapiens
E3 ligase: Iap
E3 binder: Bestatin
SMILES: show
Ligand Name: imatinib
Ligand PDB Id: STI
PDB with Ligand: 2HYY
SMILES: show
Calculated Values
MW: 842.06
Hbond donors: 7
Hbond acceptors: 10
cLogP: 6.38
TPSA: 213.35

SMILES: show
Linker type: Alkane
Incubation time (hours): 8, 24
Cells: K562
DC50: ~ 30 μM
Tested a non-binding E3 control?: No
Tested competition with ligand?: No
Tested proteaseome inhibitor?: No
Proteomics data available?: No
Tested engagement in cells?: No
Off-targets reported?: No
Comments: BCR-ABL degredation
Contributed by: Yangwode Jing, Ronen Gabizon
Calculated Values
MW: 856.09
Hbond donors: 7
Hbond acceptors: 10
cLogP: 6.77
TPSA: 213.35

SMILES: show
Linker type: Alkane
Incubation time (hours): 8, 24
Cells: K562
DC50: ~ 30 μM
Tested a non-binding E3 control?: No
Tested competition with ligand?: No
Tested proteaseome inhibitor?: No
Proteomics data available?: No
Tested engagement in cells?: No
Off-targets reported?: No
Comments: BCR-ABL degredation
Contributed by: Yangwode Jing, Ronen Gabizon